Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”) is delighted to announce the appointment of the highly experienced Dr. Francois Lebel, M.D. as Senior Vice President for preclinical and clinical development.
Dr. Lebel’s impressive record in the biopharmaceutical industry makes him an invaluable addition to the Group, enabling us to drive the discovery and development of our pioneering RNAi therapeutics even further.
Sirnaomics is delighted to announce the addition of Dr. Gilbert Lebel as Senior Vice President for Preclinical and Clinical Development. With 30 years of biopharma experience at leading companies such as GSK, Pfizer, Baxter Healthcare, Medlmmune, and Chiron Corporation, Dr. Lebel brings a wealth of knowledge and expertise in the development and marketing of novel drug products and a successful track record of product marketing authorizations at the FDA.
His invaluable experience and strategic leadership will be instrumental to the success of Sirnaomics’ multiple drug candidates as they progress through late-stage development. As Sirnaomics embarks on its journey to advancing its innovative drug candidates, we can rest assured that with Dr. Lebel at the helm of our preclinical and clinical development efforts, we have the right team and resources to reach our goal.
Dr. Lebel is thrilled to be joining the Sirnaomics team during such a defining moment for STP705, with the recent data on skin cancer being incredibly positive, and their pipeline continuing to diversify. He is eager to collaborate with the U.S. FDA and investigators to compile the needed evidence to bring it to market.
Sirnaomics is shaking up the RNA therapeutics industry, blazing a trail as the first biotech firm with a strong presence in both Asia and the United States. Their in-house delivery technologies – Polypeptide Nanoparticle Formulation and GalNAc conjugation – have been used to create a formidable product pipeline of novel drugs to tackle medical needs and diverse large markets.
Notable successes include the clinical trials for STP705 and STP707 as therapies for cancer, and now STP122G is the first drug candidate of the GalAhead™ technology advancing to clinical development. To make the leap from biotech to biopharma, Sirnaomics has set up their own manufacturing facility, setting the stage for a revolution in the RNA therapeutics space.